Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026: the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20. The company’s presence at these events underscores its commitment to engaging with the investment community as it advances its pipeline of central nervous system (CNS) and immunology treatments.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on CNS and immunology treatments in areas of high unmet medical need. The company’s recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. This approval marks a significant milestone for Tonix, providing a novel therapeutic option for patients suffering from this chronic pain condition. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
Beyond TONMYA, Tonix is maximizing the science behind this drug in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In the immunology space, Tonix is advancing a pipeline that includes monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs address significant unmet medical needs and represent potential growth drivers for the company.
Investors interested in learning more about Tonix’s strategy and pipeline can follow the company’s newsroom at https://ibn.fm/TNXP for the latest updates. The full press release regarding the investor conferences is available at https://ibn.fm/ZZpG2. As Tonix continues to execute on its commercial and clinical objectives, its participation in these conferences provides a platform to communicate its progress and potential to the investment community.
